Skip to content

Effects of Lactobacillus delbrueckii and Streptococcus thermophillus on tailored triple therapy for Helicobacter pylori eradication

Effects of Lactobacillus delbrueckii and Streptococcus thermophillus on tailored triple therapy for Helicobacter pylori eradication: A prospective randomized controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20141209001
Enrollment
Unknown
Registered
2014-12-09
Start date
2014-06-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advert event and number of patients Helicobacter pylori eradication

Interventions

one week tailored triple therapy (esomeprazole 20 mg bid&#44
clarithromycin 500 mg bid or metronidazole 400 mg tid if clarithromycin resistance and amoxicillin 1000 mg bid
group1&#44
n = 100)
one week of pre&#45
treatment with probiotics (group2&#44
n = 100),one week of pre&#45
treatment with probiotics (Lactobacillus delbrueckii and Streptococcus thermophillus),one week of pre&#45
treatment probiotic before tailored triple therapy then followed by one weeks of the same probiotics after treatment with tailored triple therapy (Lactobacillus delbrueckii and Streptococcus thermophi
Placebo Comparator Drug,Experimental Dietary Supplement,Experimental Dietary Supplement
tailored triple therapy alone,one week of pre&#45
treatment with probiotics,one week of pre&#45
treatment probiotic before tailored triple therapy then followed by one weeks of the

Sponsors

institute of reserch and development, Suranaree University of Technology
Lead Sponsor
Suranaree University of Technology Hospital
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Helicobacter pylori associated gastritis

Exclusion criteria

Exclusion criteria: age below 18 or above 70 years, previous Helicobacter pylori eradication treatment before previous 2 months, gastric ulcer or duodenal ulcer, suspected or confirmed malignancy on endoscopy, significant medical illnesses and history of previous gastric surgery, pregnant or lactating women, and the use of antimicrobials or gastrointestinal medications like PPIs or bismuth compounds within the previous 2 months, refuse yogurt due to underlying disease such as DM ,history of drug allergy in first line therapy

Design outcomes

Primary

MeasureTime frame
Administration of probiotic to pre-treatment and post-treatment tailored triple therapy can improve 1 month after treatment eradication rate after complete theraputic protocal

Secondary

MeasureTime frame
advert event during thraputic peroid 1 month after treatment number and percent of advert event during treatment

Countries

Thailand

Contacts

Public Contacttaweesak tongtawee

department of surgery

taweesak.t@sut.ac.th0819010891

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026